The Geographical Distribution of Leadership in Globalized Clinical Trials

Por Hoekman, Jarno, Frenken, Koen, de Zeeuw, Dick, Heerspink, Hiddo Lambers
Publicado em 2012

The Use of Surrogate Endpoints in Regulating Medicines for Cardio-Renal Disease: Opinions of Stakeholders

Por Schievink, Bauke, Lambers Heerspink, Hiddo, Leufkens, Hubert, De Zeeuw, Dick, Hoekman, Jarno
Publicado em 2014

Drug-Induced Reduction in Albuminuria Is Associated with Subsequent Renoprotection: A Meta-Analysis

Por Lambers Heerspink, Hiddo J., Kröpelin, Tobias F., Hoekman, Jarno, de Zeeuw, Dick
Publicado no J Am Soc Nephrol (2015)

FDA Facilitated Regulatory Pathways: Visualizing Their Characteristics, Development, and Authorization Timelines

Por Liberti, Lawrence, Bujar, Magda, Breckenridge, Alasdair, Hoekman, Jarno, McAuslane, Neil, Stolk, Pieter, Leufkens, Hubert
Publicado no Front Pharmacol (2017)

Characteristics and follow‐up of postmarketing studies of conditionally authorized medicines in the EU

Por Hoekman, Jarno, Klamer, Thea T., Mantel‐Teeuwisse, Aukje K., Leufkens, Hubert G. M., De Bruin, Marie L.
Publicado no Br J Clin Pharmacol (2016)

An analysis of marketing authorisation applications via the mutual recognition and decentralised procedures in Europe

Por Ebbers, Hans C., Langedijk, Joris, Bouvy, Jacoline C., Hoekman, Jarno, Boon, Wouter P. C., de Jong, Jean Philippe, De Bruin, Marie L.
Publicado no Eur J Clin Pharmacol (2015)

Adverse Drug Reaction Reporting in Africa and a Comparison of Individual Case Safety Report Characteristics Between Africa and the Rest of the World: Analyses of Spontaneous Report...

Por Ampadu, Haggar H., Hoekman, Jarno, de Bruin, Marieke L., Pal, Shanthi N., Olsson, Sten, Sartori, Daniele, Leufkens, Hubert G. M., Dodoo, Alexander N. O.
Publicado no Drug Saf (2016)